臺北市
--°
( --° / --° )
氣象
快訊

2020-05-06 | 公共電視

Adimmune Corp Develops Vaccine for COVID-19|國光研發候選疫苗 台大試驗後證實有效

Taiwanese vaccine manufacturer Adimmune Corporation announced that company's candidate vaccine for the novel coronavirus has been proven effective in animal trials. The company hopes to start mass production by next winter when it passes human clinical trials.

As COVID-19 continues to threaten countries around the globe and seems to be lingering, the Taiwanese vaccine manufacturer Adimmune Corporation has successfully developed a candidate vaccine for the coronavirus after 4 months of hard work. It has been proven effective in the neutralization antibody assay conducted in the virology lab of the National Taiwan University.

We have picked the most deadly virus strain which is mainly found in Europe for the test. The test result showed the serum antibody in the vaccine can actually neutralize the virus and effectively suppress the virus. Therefore we are quite confident.

To develop this self-developed candidate vaccine, researchers used genetic sequencing and recombination to yield valid data, then conducted neutralization antibody assays in the lab. During these tests, mice injected with the vaccine had a stronger antibody reaction, producing a higher concentration of antibody to suppress the virus. When diluted, the antibody is still strong enough to prevent the virus from causing an infection. Adimmune estimates that it could begin the first phase of human clinical trials in the third quarter of 2020 after it obtains approval.

The reshuffled protein needs to be processed several times than the usual proteins before it can be injected into the human body. The work required is doubled with two layers of protection before it can be injected into the human body. Therefore the vaccine is more reliable and effective but more processing time is needed beforehand.

Adimmune stressed that it will collaborate with the National Health Research Institutes (NHRI) to start a challenge test to ensure the safety of the candidate vaccine. Its defect rate during the manufacturing process is also hard to predict. With that being said, the company is confident that the vaccine it produces will be sufficient for the 23 million people in Taiwan even in the worst case scenario. The company hopes to start mass production by next winter.

武漢肺炎疫情目前仍在全球擴散,而且沒有立即消失的跡象,經過4個月努力,國光生技成功自主研發武漢肺炎候選疫苗,並在台大病毒實驗室進行疫苗抗體中和試驗後證實有效。

台大醫學院生物技術學系教授 張淑媛表示:「我們目前挑的是我們手裡面,我們覺得毒性最強的病毒,就是主要在歐洲流行的一個病毒株,所以在看到這樣實驗結果,其實這個疫苗的血清抗體,真的可以中和這個病毒,很有效的抑制,其實我們是滿有信心的。」

這支自主研發的候選疫苗,主要是透過病毒基因排序與基因重組等方式尋找有效數據,並在實驗室中進行疫苗抗體中和試驗,結果在注射新冠疫苗的小鼠血清中,發現小鼠抗體反應優異,可引發高力價中和抗體、有效抑制病毒,血清抗體經高度稀釋後仍足以讓新冠病毒失去感染力,預計今年第3季可獲准開始第1期人體臨床試驗。

國光生技董事長 詹啟賢表示:「這重組蛋白,要進入人體之前,所經過的程序,比一般的多。多了兩層的工作,經過雙重的保護,再打到人體之後,它的這個可靠性比較強,但是前面準備的工作要比較慢。」

國光生技強調,接下來將與國衛院合作進行攻毒試驗確認新冠候選疫苗的安全性,但由於該疫苗是全新的疫苗,良率難以預料,即使以最差良率評估,仍足夠台灣2300萬人使用,希望最快明年冬天能展開量產。

最新生活新聞

延伸閱讀